-
Mashup Score: 29Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer - 9 day(s) ago
The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the influence of B-cell tumor infiltration on overall patient survival remains unclear.
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 8ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer - 1 month(s) ago
This interim update provides new recommendations for the following ESMO Clinical Practice Guideline (CPG): Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.1
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer - ESMO Open https://t.co/Ngv7KnBWxt
-
-
Mashup Score: 1Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial - 2 month(s) ago
The IMvigor210 trial demonstrated clinical benefit and manageable toxicity with atezolizumab monotherapy [anti-programmed death-ligand 1 (PD-L1)] in patients with metastatic urothelial carcinoma (UC) in primary analyses. Final efficacy and safety results after long-term follow-up are reported.
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet-
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial - ESMO Open https://t.co/Rvy0Relyw5
-
-
Mashup Score: 2
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology study in patients with aRCC (FRACTION-RCC) was designed to assess new immuno-oncology (IO) combinations in patients with advanced renal cell carcinoma (aRCC). We present results in IO-naive patients treated with nivolumab (NIVO) + relatlimab (RELA) or NIVO + ipilimumab (IPI) in track 1.
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet-
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial - ESMO Open https://t.co/1Xx9BTKo2O
-
-
Mashup Score: 5Home Page: ESMO Open - 2 month(s) ago
Published online: August 29, 2024 Published online: September 5, 2024 Published online: September 5, 2024 Published online: September 9, 2024 Published online: September 4, 2024 International guidelines strongly recommend the use of the homologous recombination deficiency (HRD) test in the selection of first-line maintenance therapy for patients with high-grade serous ovarian cancer. The test has significant prognostic and, importantly, predictive value for the response to PARP inhibitors. However, in
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet-
Want to publish your oncology research? Discover what makes ESMO Open unique from the perspective of our Editor-in-Chief, Professor Giuseppe Curigliano. Watch the video now: For more info, visit https://t.co/QkhRU1o6e4 @ESMO_Open https://t.co/C6eDgsDrDb
-
-
Mashup Score: 36Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society - 2 month(s) ago
For almost five decades, the European Society for Medical Oncology (ESMO) has brought people together from all over the world to improve cancer care. However, these activities, especially international congresses, contribute to climate change.1 Therefore, ESMO created the Climate Change Task Force, whose remit is to examine the impact of ESMO’s activities on greenhouse gas emissions and produce recommendations to reduce the society’s carbon footprint.2
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
🚆 🚂 from Brussels 🇧🇪 to Berlin 🇩🇪 and #ESMOBreast24 A reminder of this Editorial for a sustainable society in @ESMO_Open from the @myESMO Climate Change Task Force 🌱 🌍 I look forward to meeting you there! #ESMOAmbassadors @TraintoESMO https://t.co/QTogGad8n4 https://t.co/Y3C8ZJLrnN
-
-
Mashup Score: 5Home Page: ESMO Open - 2 month(s) ago
Published online: August 29, 2024 Published online: September 5, 2024 Published online: September 5, 2024 Published online: September 9, 2024 Published online: September 4, 2024 International guidelines strongly recommend the use of the homologous recombination deficiency (HRD) test in the selection of first-line maintenance therapy for patients with high-grade serous ovarian cancer. The test has significant prognostic and, importantly, predictive value for the response to PARP inhibitors. However, in
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet-
Want to publish your oncology research? Discover what makes ESMO Open unique from the perspective of our Editor-in-Chief, Professor Giuseppe Curigliano. Watch the video now: For more info, visit https://t.co/QkhRU1o6e4 @ESMO_Open https://t.co/C6eDgsDrDb
-
-
Mashup Score: 3ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology - 2 month(s) ago
Burnout in health care professionals (HCPs) results from exposure to psychosocial risks at work. Left unaddressed, burnout can lead to chronic health problems, increased staff turnover, reduced work hours, absenteeism, and early retirement from clinical practice, thus impacting patient care. The European Society for Medical Oncology (ESMO) Resilience Task Force (RTF) was established in December 2019 to support the well-being of oncology HCPs globally. This ESMO RTF position paper aims to provide a set of recommendations to optimise well-being and mitigate burnout in oncology, and to help individuals and institutions maintain the delivery of optimal cancer care.
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet-
To learn more read the recommendations: https://t.co/u8D2sVaHaF
-
-
Mashup Score: 129
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
One of the most important #globaloncology #cancerpolicy studies our group has published. https://t.co/YYGNMhbecW We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit… https://t.co/DkJqL4pibQ https://t.co/ImcIkYahjR
-
-
Mashup Score: 129
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
One of the most important #globaloncology #cancerpolicy studies our group has published. https://t.co/YYGNMhbecW We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit… https://t.co/DkJqL4pibQ https://t.co/ImcIkYahjR
-
Hot off the press - an IGG gene signature links to longevity in breast cancer survivors, reduced death risk across cancers, and it correlates with TLS and B-/T-cell polyclonality. https://t.co/cl3X1X94Ea https://t.co/1EWGX2Wl2u